Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

This study is testing a new combination of treatments — using a targeted therapy (olaparib) alongside and after standard chemotherapy — for people with a specific type of breast cancer called triple-negative breast cancer (TNBC) who also carry a BRCA1 or BRCA2 gene mutation. These gene mutations increase the cancer's vulnerability to certain drugs. **You may be eligible if...** - You are 18 or older - You have been diagnosed with invasive triple-negative breast cancer (TNBC) confirmed by biopsy - You have a germline (inherited) BRCA1 or BRCA2 mutation - Your cancer has not yet spread to distant organs (non-metastatic) but is locally advanced - You have not previously received treatment for this cancer - Your general health status is good (ECOG 0–1) **You may NOT be eligible if...** - You are pregnant (confirmed by pregnancy test) - You have inflammatory breast cancer - You have received prior chemotherapy or immunotherapy for this cancer - You have significant cardiovascular or gastrointestinal problems Talk to your doctor to see if this trial is right for you.